Arrowhead Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Arrowhead Pharmaceuticals is Chris Anzalone, benoemd in Dec2007, heeft een ambtstermijn van 16.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.92M, bestaande uit 9.1% salaris en 90.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.99% van de aandelen van het bedrijf, ter waarde $ 67.91M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 14 jaar.
Belangrijke informatie
Chris Anzalone
Algemeen directeur
US$9.9m
Totale compensatie
| Percentage CEO-salaris | 9.1% |
| Dienstverband CEO | 16.9yrs |
| Eigendom CEO | 3.0% |
| Management gemiddelde ambtstermijn | 6.4yrs |
| Gemiddelde ambtstermijn bestuur | 14yrs |
Recente managementupdates
Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
Compensatie versus markt: De totale vergoeding ($USD 9.92M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.43M ).
Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chris Anzalone (55 yo)
16.9yrs
Tenure
US$9,918,093
Compensatie
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 67.9m | |
| Chief Financial Officer | 14.8yrs | US$3.12m | 0.19% $ 4.3m | |
| COO, General Counsel & Secretary | 9.9yrs | US$3.31m | 0.23% $ 5.2m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 3.7m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | geen gegevens | geen gegevens | |
| Head of Investor Relations & VP | no data | geen gegevens | geen gegevens | |
| Director of Communications | 19.3yrs | geen gegevens | geen gegevens | |
| Chief Medical Scientist | less than a year | US$16.34m | geen gegevens | |
| Head of Toxicology & VP | no data | geen gegevens | geen gegevens | |
| Head of Tax | 2.8yrs | geen gegevens | geen gegevens | |
| SVP of Cardiovascular & Head of Metabolic Franchise | no data | geen gegevens | geen gegevens | |
| VP & Treasurer | 2.8yrs | geen gegevens | geen gegevens |
6.4yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ARWR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 67.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | geen gegevens | geen gegevens | |
| Chairman of the Board | 14yrs | US$474.60k | 0.11% $ 2.6m | |
| Independent Lead Director | 12.9yrs | US$459.60k | 0.074% $ 1.7m | |
| Independent Director | 6.8yrs | US$469.60k | 0.026% $ 601.1k | |
| Member of Hepatitis B Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 14.3yrs | US$459.60k | 0.037% $ 837.0k | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Hepatitis B Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Hepatitis B Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Hepatitis B Clinical Advisory Board | no data | geen gegevens | geen gegevens |
14.0yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ARWR zijn ervaren en ervaren (gemiddelde ambtstermijn van 14 jaar).